Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.
Invetx has raised $60.5M in total funding. The most recent round was Series B. The last funding was announced in May 2022.
Invetx's investors include Novo Holdings, F-Prime, Google Ventures, Casdin Capital, Eight Roads Ventures.
Invetx is headquartered in Boston, United States.
Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.
Invetx is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Invetx — Funding & Investors." VCBacked, May 10, 2022, https://www.vcbacked.co/company/invetx. Accessed July 19, 2026.
VCBacked. (2022). Invetx — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/invetx
{{cite web |title=Invetx — Funding & Investors |url=https://www.vcbacked.co/company/invetx |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated